Basis: (FMP quote price / unrounded diluted TTM EPS) / five-year diluted EPS CAGR in percent, from annual statements through the period end shown. Source: stored company filings and market data; unavailable inputs remain N/A.
The PEG ratio is N/A as of 2026-10-06T13:35:56.205Z.
Calculation as of: 2026-10-06T13:35:56.205Z.
Quote observation: 2026-10-06T13:35:11.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 604c485faa117edd7b478e74db8828d7312282746a460099f8cc32b45e3ebf42
PEG RATIO
N/A
| NAME | MARKET CAP | PEG RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Caris Life Sciences, Inc. (CAI) | $9.08B | N/A | N/A | N/A | N/A |
| Kymera Therapeutics, Inc. (KYMR)vs › | $8.97B | N/A | N/A | N/A | N/A |
| Axsome Therapeutics, Inc. (AXSM)vs › | $8.98B | N/A | N/A | N/A | N/A |
| Insulet Corp. (PODD)vs › | $9.37B | 0.24 | 0.59 | 0.53 | 0.53 |
| Arrowhead Pharmaceuticals, Inc. (ARWR)vs › | $8.75B | N/A | N/A | N/A | N/A |
| Bruker Corporation (BRKRP)vs › | $9.57B | N/A | N/A | N/A | N/A |
| Henry Schein, Inc. (HSIC)vs › | $9.76B | 7.90 | 7.70 | 5.62 | 3.64 |
| Oscar Health, Inc. (OSCR)vs › | $8.41B | N/A | N/A | N/A | N/A |
| Krystal Biotech, Inc. (KRYS)vs › | $9.78B | N/A | N/A | N/A | N/A |
| Bruker Corporation (BRKR)vs › | $10.00B | N/A | 1.30 | 1.52 | 2.14 |
PEG Ratio
N/A
P/E Ratio
89.7
PEG Ratio = P/E Ratio / 5-Year Diluted EPS CAGR (%)
The PEG ratio divides the price-to-earnings ratio by the company's five-year compound annual growth rate of diluted EPS, expressed in percent. A P/E of 20 and a five-year diluted EPS CAGR of 10% give a PEG of 2.0. The growth is reported, historical earnings growth from annual statements, not an analyst forecast. A PEG near 1 is often read as fairly priced for its growth; lower can mean cheaper relative to growth. The ratio is N/A when the P/E is unavailable or not positive, or when the five-year diluted EPS CAGR is unavailable or not positive. Each day of the history uses the CAGR that was known on that day.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
